Hill-Rom Holdings, Inc. HRC
Hill-Rom is a low-quality medical roll-up whose plateauing new products, exhausted margin expansion and aggressive accounting point to a 25-55% drop to $45-$75 per share.
Thesis
Spruce Point argues Hill-Rom is a $3.5B-assembled medical-equipment roll-up masking flat organic growth with a fluid 'core growth' metric, new-product releases like the Centrella smart bed, and serial divestitures of low-margin businesses. Stripping out new-product contribution, legacy core growth has averaged -1.5% to 0.7% over eight quarters, setting up a Q4 FY19 consensus miss of 2-4%. Margin expansion since FY16 is largely divestiture-driven and will exhaust by year-end FY20 as 4.5x leverage limits further M&A. Meanwhile management has under-reserved by ~$55M cumulatively, underspent capex by 20-30% for years, and lost its CEO, CFO, CIO and two of three division heads in two years while insiders dumped stock. Reversing management's EBITDA adjustments and applying peer multiples, Spruce Point sees 25-55% downside to $45-$75 per share.
SCQA
Hill-Rom is a $6.8B NYSE-listed hospital-bed and medical-device roll-up built via $3.5B of acquisitions since FY09, marketed to investors as a mid-single-digit 'core growth' story with expanding margins.
Core growth is a self-defined metric that masks flat organic sales: new-product revenue has plateaued, margin gains came from divestitures now ending, leverage caps further M&A, and aggressive accounting and revolving CFOs have flattered earnings.
Short HRC. Discount 'core growth,' reverse management's EBITDA and earnings adjustments for recurring acquisition and restructuring costs, and re-rate the stock toward peers on honest metrics.
Base-case $60.51, bear-case $46.91, bull-case $74.81 per share versus $100.50 — 26%-53% downside, with a near-term Q4 FY19 revenue miss of 2.5%-4.1% versus consensus as the first catalyst.
The three reasons
- 1
New-product growth has plateaued, exposing flat-to-negative organic core growth underneath
- 2
Divestiture-driven margin expansion is nearly exhausted; leverage caps further roll-up M&A
- 3
Aggressive accounting, chronic capex underspend and insider selling under a revolving-door C-suite
Primary demands
- Short HRC shares given 25-55% downside to $45-$75 per share
- Discount management's 'core growth' metric as a fluid, self-serving KPI
- Reverse EBITDA and earnings adjustments for recurring acquisition and restructuring costs
- Scrutinize chronic capex under-spend and pending goodwill impairments (~$500M, ~11% of assets)
KPIs cited
Pattern membership
Precedents cited
- Newell Brands (CFO Steven Strobel's prior roll-up, inventory channel-stuffing allegations)
- Mallinckrodt (replacement CFO Barbara Bodem's prior scandal-tainted pharma roll-up)
- Caesarstone, A.O. Smith, Gentex (prior Spruce Point targets with capex mis-forecasting)
- CECO Environmental, LKQ, AMETEK, XPO Logistics (Spruce Point's prior successful short-sell roll-up campaigns)
Composition what's on the 80 slides
Slide gallery ·
Notes
Classic Spruce Point short report on a serial acquirer. Striking conceptual cover art (decaying patient in hospital bed, SELL monitor, rats) sits above a generally conservative teal/grey institutional layout — the cover is a notable craft moment. Page 3 'Success Shorting Sleepy Roll-Up Stories' functions as a credibility block citing prior wins (CECO, LKQ, AMETEK, XPO). Two-page executive summary (pp. 6-7) is dense prose that reads almost like a legal brief. Page 40 uses verbatim CEO (John Greisch) and IR (Mary Kay Ladone) earnings-call quotes to catch management walking back new-product cannibalization claims — strong 'management contradicts itself' specimen. Target ticker is NYSE:HRC. No stake disclosed; Spruce Point flags a short position in the legal disclaimer on page 2. Precedent citations are unusually playbook-oriented: they anchor villainy to CFO Steven Strobel's Newell tenure and successor Barbara Bodem's Mallinckrodt tenure.